Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ANVS

ANVS - Annovis Bio Inc Stock Price, Fair Value and News

$3.05+0.15 (+5.17%)
Market Closed

32/100

ANVS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

32/100

ANVS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.41

Target 3M

$2.84

Target 6M

$2.68

ANVS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANVS Price Action

Last 7 days

5.9%

Last 30 days

-12.9%

Last 90 days

46.6%

Trailing 12 Months

-37.2%

ANVS RSI Chart

ANVS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANVS Valuation

Market Cap

80.8M

Price/Earnings (Trailing)

-3.25

Price/Sales (Trailing)

3.7K

EV/EBITDA

-2.93

Price/Free Cashflow

-3.24

ANVS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.41

Target 3M

$2.84

Target 6M

$2.68

ANVS Fundamentals

ANVS Revenue

Revenue (TTM)

36.8K

ANVS Earnings

Earnings (TTM)

-24.9M

Earnings Growth (Yr)

42.53%

Earnings Growth (Qtr)

-16.76%

ANVS Profitability

EBT Margin

-111386.81%

Return on Equity

-189.15%

Return on Assets

-144.77%

Free Cashflow Yield

-30.9%

ANVS Investor Care

Shares Dilution (1Y)

92.09%

Diluted EPS (TTM)

-1.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2021877.3K597.1K316.9K36.8K
2020840.7K946.3K1.1M1.2M
2019000735.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About Annovis Bio Inc

ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
 CEO
 WEBSITEannovisbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

Annovis Bio Inc Frequently Asked Questions

ANVS is the stock ticker symbol of Annovis Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Annovis Bio Inc is 80.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ANVS's fair value in chart for subscribers.

The fair value guage provides a quick view whether ANVS is over valued or under valued. Whether Annovis Bio Inc is cheap or expensive depends on the assumptions which impact Annovis Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANVS.

As of Wed Jan 28 2026, ANVS's PE ratio (Price to Earnings) is -3.25 and Price to Sales (PS) ratio is 3.68 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANVS PE ratio will change depending on the future growth rate expectations of investors.